

## **IMPORTANT DATES:**

- I. 6/6/2017: You must let Nikki Adams know if you plan to submit an investigator initiated trial/study to compete for the \$50,000 awarded via the SHARK TANK Session.**
- II. 6/15/17: Send Nikki Addams completed attached slides of the proposed trial/study for judges to review.**
- III. 6/23/17 at 4 p.m.: Someone from your team must pitch your idea at the Glenn Family Breast Center Retreat, for 5-10 minutes. Time will be allocated based on number of competing teams.**

## **TIPS FOR SUCCESS at the SHARK TANK:**

1. The judges have expertise in trial/study development and research in cancer **but not necessarily** breast cancer. Therefore, you must make strong arguments in the following areas:
  - a. Why your proposed study/trial is pertinent and addresses a significant problem facing breast cancer patients
  - b. How your trial/study will be completed by accruing patients from the Glenn Family Breast Center in a 30 month period and reach endpoints within a 36 month period (FEASIBILITY)
2. Multidisciplinary teams – statistician, MD, basic scientists, public health scientist, imager and/or pathologist often come up with the most innovative and scientifically sound proposals. Preference will be given to teams with a mix of junior, mid-level and senior investigators.
3. Multidisciplinary teams who propose studies with high potential for publication, expansion into the cooperative groups or multi-institutional trials, and/or lead to extramural funding will be most competitive.
4. Engaging with a statistician is **highly encouraged if not mandatory** for trial design and power analysis.
5. Research must be original, investigator-initiated and involve Emory Glenn Family Breast Cancer Patients.
6. You will be given 5-10 minutes to pitch your idea, the audience will then be allowed to ask questions, and a non-partisan SHARK TANK panel of judges will provide feedback.

Therapeutic and non-therapeutic, prospective studies are eligible.

7. **\*\*To receive full funding, the winning team must have complete IRB approval for their study by April 2018. The normal Winship pilot grant rules apply as far as money allocation.**

**Priority will be given to studies in the following areas:**

1. Ductal Carcinoma In Situ (DCIS)
2. Neoadjuvant treatment trials
3. Hormone refractory hormone receptor positive metastatic breast cancer
4. Plastics/Reconstruction
5. Breast imaging
6. Health literacy/behavior
7. Local therapy studies - surgery or radiation
8. Disparities pertinent to our Atlanta community and the state of Georgia
9. Immune therapy/inflammation

**Exclusion Criteria:**

1. Please note that only prospective studies involving patients who are consented to participate are eligible. Retrospective studies or studies accessing samples from tissue bank or path department only are NOT eligible. All studies must be prospective and involve patients [either therapeutic or observational/non-therapeutic (biomarker or imagine) correlative studies].
2. Studies already enrolling patients are NOT eligible.